Well, I was hopeful we would get the secondary endpoint data to cushion us if we missed topline.
That being said, on the conference call they told us everything they legally could to hold on. It sounds to me that they have seen all the data and that is why they are confident.
You'll recall in 2013 it was still up in the air up 208 would continue to be developed.
It is clear in the presser that they feel continued development is warranted.
A few possibilities....
Crestor subgroup is significant....RVX owns the combo patent
Renal data is compelling....huge market
Neuro data is compelling....also a huge market.
I'll wait until the big reveal in November.
bfw
